Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SFDA Kicks Off Drug Re-registration Examination And Approval

This article was originally published in PharmAsia News

Executive Summary

To ensure drug safety and eliminate low-quality and high-risk drugs, China's State FDA has officially started drug re-registration examinations and approvals. All provincial drug administrations will refer to the drug management methodology to conduct integrated checks on drug approval numbers, production techniques and prescription investigation results. Drugs will not be re-registered if their approval numbers are not genuine. In addition, SFDA demands that all provincial drug administrations set up records for drug re-registration to improve quality control and support routine supervision and on-site inspections. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072503

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel